Cargando…
Universal endogenous antibody recruiting nanobodies capable of triggering immune effectors for targeted cancer immunotherapy
Developing monoclonal antibodies (mAbs) for cancer immunotherapy is expensive and complicated. Nanobodies are small antibodies possessing favorable pharmacological properties compared with mAbs, but have limited anticancer efficacy due to the lack of an Fc region and poor pharmacokinetics. In this c...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Royal Society of Chemistry
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179521/ https://www.ncbi.nlm.nih.gov/pubmed/34163726 http://dx.doi.org/10.1039/d0sc05332e |